Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.
CRISPR Therapeutics AG is rated a Buy with $1.9B cash, prudent management, and undervalued shares. Learn more about CRSP ...
Positive Phase 1 data for CTX310® presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions and ...
ANTLER phase 1 data demonstrate efficacy and durability on par with autologous CAR-T cell therapy and safety allows for ...
Detailed price information for Caribou Biosciences Inc (CRBU-Q) from The Globe and Mail including charting and trades.
According to the 13F filing with the Securities and Exchange Commission dated Nov. 12, 2025, ARK Investment Management sold ...
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...
Thinking about CRISPR Therapeutics and wondering if now is your chance to scoop up value, or if the stock is already priced in with the excitement? Let's break down what the numbers and news say about ...
Zacks Investment Research on MSN
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at ...
Investor's Business Daily on MSN
Why Gene-Editing Giants Crispr And Intellia Just Surged
Crispr stock jumped Monday while Intellia shares surged on promising updates for their gene-editing efforts in cholesterol ...
Promising results from a small clinical trial highlight a growing interest in designing gene-editing treatments for common ...
ARK also continued its buying trend in CRISPR Therapeutics AG (NASDAQ:CRSP), acquiring 39,250 shares valued at $2,142,265. This purchase adds to the fund’s recent accumulation of CRISPR stock over the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback